-

Pegasystems, Inc. Investor News: Robbins LLP is Investigating Pegasystems Inc. (PEGA) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Pegasystems Inc. (NASDAQ: PEGA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws by stealing Pegasystems' competitor's trade secrets. Pegasystems develops customer relationship management ("CRM") software.

If you would like more information about our investigation of Pegasystems Inc.'s misconduct, click here.

What is this Case About: According to the complaint filed against Pegasystems, Pegasystems' products and the revenue generated from those products were, in large part, the result of theft of trade secrets from one of its competitors. On May 29, 2020, Appian Corporation sued Pegasystems for stealing its trade secrets and violating Virginia's computer crime law.

Pegasystems, in violation of SEC reporting requirements, for two years did not publicly disclose Appian's lawsuit in its public SEC filings. On May 9, 2022, Pegasystems disclosed that the Virginia circuit court jury awarded Appian more than $2 billion for Pegasystems' trade secret misappropriation, which is estimated to be the largest damages award in Virginia circuit court history. On this news, Pegasystems' stock price fell 21% and lost over $1 billion in market capitalization, closing at $52.25 on May 10, 2022. Securities analysts voiced their concerns of the news, lowering their ratings and noting that the lawsuit, misconduct, and jury verdict would negatively impact the Company's ability to obtain future business, including contracts with governmental authorities.

Next Steps: If you acquired shares of Pegasystems Inc. (PEGA) common stock between May 29, 2020 and May 9, 2022, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Pegasystems Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:PEGA

Release Summary
Robbins LLP is Investigating Pegasystems Inc. (PEGA) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Al...

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...
Back to Newsroom